Blood doping: present procedures and detection techniques

References

• Berglund B, Hemmingson P. Effect of reinfusion of autologous blood on exercise performance in cross-country skiers. Int. J. Sports Med.8(3), 231–233 (1987).
   Google Scholar
• Berglund B, Hemmingsson P, Birgegard G. Detection of autologous blood transfusions in cross-country skiers. Int. J. Sports Med.8(2), 66–70 (1987).
   PubMed Web of Science ®Google Scholar
• Gareau R, Gagnon MG, Thellend G et al. Transferrin soluble receptor: a possible probe for detection of erythropoietin abuse by athletes. Horm. Metab. Res.26, 311–312 (1994).
   Google Scholar
• Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br. J. Clin. Pharmacol.42(3), 355–364 (1996).
   Google Scholar
• Casoni I, Ricci G, Ballarin E et al. Hematological indices of erythropoietin administration in athletes. Int. J. Sports Med.14, 307–311 (1993).
   Google Scholar
• Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature405, 635 (2000).
   PubMed Web of Science ®Google Scholar
• Parisotto R, Gore CJ, Emslie KR et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica85(6), 564–572 (2000).
   PubMed Web of Science ®Google Scholar
• Castelli G, Famularo A, Semino C et al. Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol. Res.41(3), 313–318 (2000).
   PubMed Web of Science ®Google Scholar
• Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med.346(7), 469–475 (2002).
   PubMed Web of Science ®Google Scholar
• Ninot G, Connes P, Caillaud C. Effects of recombinant human erythropoietin injections on physical self in endurance athletes. J. Sports Sci.24(4), 383–391 (2006).
   PubMed Web of Science ®Google Scholar
• Lasne F. Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. J. Immunol. Methods253(1–2), 125–131 (2001).
   PubMed Web of Science ®Google Scholar
• Lasne F. Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J. Immunol. Methods276(1–2), 223–236 (2003).
   PubMedGoogle Scholar
• Schubert A, O’Hara JF Jr, Przybelski RJ et al. Effect of diaspirin crosslinked hemoglobin (DCLHb HemAssist) during high blood loss surgery on selected indices of organ function. Artif. Cells Blood Substit. Immobil. Biotechnol.30(4), 259–283 (2002).
   PubMed Web of Science ®Google Scholar
• Winslow RM. MP4, a new nonvasoactive polyethylene glycol–hemoglobin conjugate. Art. Organs28, 800–806 (2004).
   PubMed Web of Science ®Google Scholar
• Levy JH, Goodnough LT, Greilich PE et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J. Thorac. Cardiovasc. Surg.12, 35–42 (2002).
   Google Scholar
• Mathurin JC, de Ceaurriz J, Audran M, Krafft MP. Detection of perfluorocarbons in blood by headspace solid-phase microextraction combined with gas chromatography/mass spectrometry. Biomed. Chromatogr.15(7), 443–451 (2001).
   Google Scholar
• Gaudard A, Varlet-Marie E, Bressolle F, Audran M. Drugs for increasing oxygen and their potential use in doping: a review. Sports Med.33(3), 187–212 (2003).
   PubMed Web of Science ®Google Scholar
• Wright-Carpenter T, Klein P, Schaferhoff P, Appell HJ, Mir LM, Wehling P. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int. J. Sports Med.25(8), 588–593 (2004).
   PubMed Web of Science ®Google Scholar
• Amorino GP, Lee H, Holburn GE et al. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. Radiat. Res.156(3), 294–300 (2001).
   PubMed Web of Science ®Google Scholar
• Breidbach A, Catlin DH. RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry. Rapid Commun. Mass Spectrom.15(24), 2379–2382 (2001).
   PubMedGoogle Scholar
• Stead RB, Lambert J, Wessels D et al. Evaluation of the safety and pharmacodynamics of HematideTM, a novel erythropoietic agent, in a Phase 1, double-blind, placebo-controlled, dose escalation study in healthy volunteers. Blood108(6), 1830–1834 (2006).
   PubMed Web of Science ®Google Scholar
• Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep.4(6), 436–440 (2005).
   PubMedGoogle Scholar
• McCrory P. Super athletes or gene cheats? Br. J. Sports Med.37(3), 192–193 (2003).
   PubMed Web of Science ®Google Scholar
• Azzazy HM, Mansour MM, Christenson RH. Doping in the recombinant era: strategies and counterstrategies. Clin. Biochem.38(11), 959–965 (2005).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J, Kandarakis SA, Andreopoulos A, Sykiotis GP. Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med.35(10), 831–840 (2005).
   PubMed Web of Science ®Google Scholar
• Regulier E, Schneider BL, Deglon N, Beuzard Y, Aebischer P. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther.5(8), 1014–1022 (1998).
   PubMedGoogle Scholar
• Rankinen T, Perusse L, Rauramaa R, Rivera MA, Wolfarth B, Bouchard C. The human gene map for performance and health-related fitness phenotypes: the 2003 update. Med. Sci. Sports Exerc.36(9), 1451–1469 (2004).
   PubMed Web of Science ®Google Scholar
• Dine G. Biochemical and Hematological Parameters in Athletes. XIVth International Symposium on Technological Innovations in Laboratory Hematology, Montpellier, France 24–25 (2001).
   Google Scholar
• Breidbach A, Catlin DH, Green GA, Tregub I, Truong H, Gorzek J. Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin. Chem.49(6 Pt 1), 901–907 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson M, Popp H, Sharpe K, Ashenden M. Proof of homologous blood transfusion through quantification of blood group antigens. Haematologica88(11), 1284–1295 (2003).
   PubMedGoogle Scholar
• Caldini A, Moneti G, Fanelli A et al. Epoetin α, epoetin β and darbepoetin α: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. Proteomics3(6), 937–941 (2003).
   PubMedGoogle Scholar
• Minuto F, Barreca A, Melioli G. Indirect evidence of hormone abuse. Proof of doping? J. Endocrinol. Invest.26(9), 919–923 (2003).
   Google Scholar
• Beullens M, Delanghe JR, Bollen M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood107(12), 4711–4713 (2006).
   PubMed Web of Science ®Google Scholar
• Levreri I, Musante L, Petretto A, Bruschi M, Candiano G, Melioli G. Separation of human serum proteins using the Beckman-Coulter PF2D system: analysis of ion exchange-based first dimension chromatography. Clin. Chem. Lab. Med.43(12), 1327–1333 (2005).
   Google Scholar
• Bratosin D, Leszczynski S, Sartiaux C et al. Improved storage of erythrocytes by prior leukodepletion: flow cytometric evaluation of stored erythrocytes. Cytometry46(6), 351–356 (2001).
   Google Scholar
• Sparrow RL, Healey G, Patton KA, Veale MF. Red blood cell age determines the impact of storage and leukocyte burden on cell adhesion molecules, glycophorin A and the release of annexin V. Transfus. Apher. Sci.34(1), 15–23 (2006).
   PubMed Web of Science ®Google Scholar
• Sharpe K, Hopkins W, Emslie KR et al. Development of reference ranges in elite athletes for markers of altered erythropoiesis. Haematologica,87, 1248–1257 (2002).
   PubMedGoogle Scholar
• Thirup P. Haematocrit: within-subject and seasonal variation. Sports Med.33(3), 231–243 (2003).
   PubMed Web of Science ®Google Scholar
• Fairbanks VF, Tefferi A. Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to ‘apparent polycythemia’. Eur. J. Haematol.65, 285–296 (2000).
   Google Scholar
• Sawka MN, Convertino VA, Eichner ER, Schnieder SM, Young AJ. Blood volume: importance and adaptation to exercise training, environmental stresses, and trauma/sickness. Med. Sci. Sports Exerc.32, 332–348 (2000).
   PubMed Web of Science ®Google Scholar
• Vergouwen PCJ, Collée T, Marx JJM. Haematocrit in elite athletes. Int. J. Sports Med.20, 538–541 (1999).
   Google Scholar
• Schumacher YO, Gratwohl D, Barturem JM et al. Haemoglobin, haematocrit and red blood cell indices in elite cyclists. Are the control values for blood testing valid? Int. J. Sports Med.21, 380–385 (2000).
   PubMed Web of Science ®Google Scholar
• d’Onofrio G. Hematology parameters: usefulness and limitations in monitoring red cell production. Bloodline Rev.1, 5–6 (2001).
   Google Scholar
• d’Onofrio G, Zini G. Addendum to strategies to deter blood doping in sports. Haematologica87, ELT31 (2002).
   Google Scholar
• Ashenden MJ. A strategy to deter blood doping in sports. Haematologica87, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Ashenden MJ, Lacoste A, Orhant E, Audran M, Sharpe K. Longitudinal variation of hemoglobin and reticulocyte count in elite rowers. Haematologica89, 1403–1404 (2004).
   Google Scholar
• Brugnara C, Colella G, Cremins J et al. Effects of recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron deficient erythropoiesis. J. Lab. Clin. Med.123, 660–667 (1994).
   PubMed Web of Science ®Google Scholar
• Brugnara C, Colella GM, Cremins J et al. Effects of subcutaneous recombinant erythropoietin in normal subjects. J. Lab. Clin. Med.123, 660–667 (1994).
   PubMed Web of Science ®Google Scholar
• Magnani M, Corsi D, Paiardini M et al. Identification of blood erythroid markers useful in revealing erythropoietin abuse in athletes. Blood Cells Mol. Dis.27, 559–571 (2001).
   Google Scholar
• Audran M, Gareau R, Matecki SM et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med. Sci. Sports Exerc.31, 639–645 (1999).
   PubMed Web of Science ®Google Scholar
• Gareau R, Gagnon MG, Ayotte C, Chenard C, Brisson GR. rHuEPO increases urinary excretion of fibrin degradation products in haemodialysed patients. Thromb. Haemost.70, 373–374 (1993).
   Google Scholar
• Gore CJ, Parisotto R, Ashenden MJ et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica88, 333–344 (2003).
   PubMed Web of Science ®Google Scholar
• Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica85, 561–563 (2000).
   PubMed Web of Science ®Google Scholar
• Fraser CG. Analytical goals for haematology tests. Eur. J. Haematol.53(Suppl.), 2–5 (1990).
   Google Scholar
• Borel MJ, Smith SM, Derr J, Beard JL. Day-to-day variation in iron-status indices in healthy men and women. Am. J. Clin. Nutr54(4), 729–735 (1991).
   PubMed Web of Science ®Google Scholar
• Damsgaard R, Munch T, Morkcberg J, Mortensen SP, Gonzalez-Alonso J. Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: implications for antidoping strategies. Haematologica91, 141–142 (2006).
   Google Scholar
• Sharpe K, Ashenden MJ, Schumacher YO. A third generation approach to detect erythropoietin abuse in athletes. Haematologica91, 356–363 (2006).
   Web of Science ®Google Scholar